Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKRX NASDAQ:BLCM NASDAQ:EVOK NASDAQ:JAGX OTCMKTS:RGRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKRXAkorn$0.19$0.09▼$5.46$3.60M0.959.60 million shs1.19 million shsBLCMBellicum Pharmaceuticals$0.07$0.08$0.06▼$1.31$727K1.3922,874 shs6,059 shsEVOKEvoke Pharma$5.08-0.2%$5.15$1.94▼$12.32$7.93M-0.13884,826 shs30,280 shsJAGXJaguar Animal Health$1.91+2.7%$2.08$1.57▼$35.25$4.15M0.5894,656 shs58,725 shsRGRXRegeneRx Biopharmaceuticals$0.16+80,400.0%$0.03$0.00▼$0.16N/A4.6466 shs253 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKRXAkorn0.00%0.00%0.00%0.00%0.00%BLCMBellicum Pharmaceuticals0.00%0.00%0.00%0.00%0.00%EVOKEvoke Pharma-1.74%+0.59%-14.60%+86.45%+16.74%JAGXJaguar Animal Health-5.58%-10.14%-10.14%-33.09%-93.80%RGRXRegeneRx Biopharmaceuticals0.00%+80,400.00%+80,400.00%+80,400.00%+11,400.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKRXAkorn$0.19$0.09▼$5.46$3.60M0.959.60 million shs1.19 million shsBLCMBellicum Pharmaceuticals$0.07$0.08$0.06▼$1.31$727K1.3922,874 shs6,059 shsEVOKEvoke Pharma$5.08-0.2%$5.15$1.94▼$12.32$7.93M-0.13884,826 shs30,280 shsJAGXJaguar Animal Health$1.91+2.7%$2.08$1.57▼$35.25$4.15M0.5894,656 shs58,725 shsRGRXRegeneRx Biopharmaceuticals$0.16+80,400.0%$0.03$0.00▼$0.16N/A4.6466 shs253 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKRXAkorn0.00%0.00%0.00%0.00%0.00%BLCMBellicum Pharmaceuticals0.00%0.00%0.00%0.00%0.00%EVOKEvoke Pharma-1.74%+0.59%-14.60%+86.45%+16.74%JAGXJaguar Animal Health-5.58%-10.14%-10.14%-33.09%-93.80%RGRXRegeneRx Biopharmaceuticals0.00%+80,400.00%+80,400.00%+80,400.00%+11,400.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKRXAkorn 0.00N/AN/AN/ABLCMBellicum Pharmaceuticals 0.00N/AN/AN/AEVOKEvoke Pharma 0.00N/AN/AN/AJAGXJaguar Animal Health 3.00Buy$60.003,041.36% UpsideRGRXRegeneRx Biopharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKRXAkorn$682.43M0.00N/A0.19$1.86 per share0.00BLCMBellicum Pharmaceuticals$1.50M0.48N/AN/A$0.23 per share0.33EVOKEvoke Pharma$10.25M0.77N/AN/A$4.74 per share1.07JAGXJaguar Animal Health$11.69M0.35N/AN/A$12.29 per share0.16RGRXRegeneRx Biopharmaceuticals$80KN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKRXAkorn-$226.77M-$0.34N/AN/AN/A-55.64%8.53%1.31%N/ABLCMBellicum Pharmaceuticals-$24.97MN/A0.00∞N/AN/AN/A-157.93%N/AEVOKEvoke Pharma-$5.35M-$2.56N/A∞N/A-42.07%-99.48%-33.58%11/6/2025 (Estimated)JAGXJaguar Animal Health-$38.49MN/A0.00N/AN/A-344.16%-660.18%-77.42%11/12/2025 (Estimated)RGRXRegeneRx Biopharmaceuticals-$1.73MN/A0.00∞N/AN/AN/AN/AN/ALatest EVOK, AKRX, BLCM, JAGX, and RGRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025EVOKEvoke Pharma-$0.30-$0.62-$0.32-$0.62$3.80 million$3.75 million8/14/2025Q2 2025JAGXJaguar Animal Health-$7.13-$10.26-$3.13-$10.26$3.27 million$2.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKRXAkornN/AN/AN/AN/AN/ABLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AN/AJAGXJaguar Animal HealthN/AN/AN/AN/AN/ARGRXRegeneRx BiopharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKRXAkorn0.090.500.32BLCMBellicum PharmaceuticalsN/A3.043.04EVOKEvoke PharmaN/A1.371.32JAGXJaguar Animal Health2.440.950.59RGRXRegeneRx BiopharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKRXAkorn64.03%BLCMBellicum Pharmaceuticals4.93%EVOKEvoke PharmaN/AJAGXJaguar Animal Health12.04%RGRXRegeneRx BiopharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipAKRXAkorn3.90%BLCMBellicum Pharmaceuticals10.30%EVOKEvoke Pharma2.29%JAGXJaguar Animal Health4.55%RGRXRegeneRx Biopharmaceuticals12.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKRXAkorn2,227133.15 millionN/AOptionableBLCMBellicum Pharmaceuticals139.72 million8.72 millionNot OptionableEVOKEvoke Pharma41.56 million1.52 millionNot OptionableJAGXJaguar Animal Health502.17 million2.08 millionNo DataRGRXRegeneRx Biopharmaceuticals3N/AN/ANot OptionableEVOK, AKRX, BLCM, JAGX, and RGRX HeadlinesRecent News About These CompaniesEIGRQ Eiger BioPharmaceuticals, Inc.July 19, 2024 | seekingalpha.comThe Hawryluk Biopharmaceutical ScholarsJanuary 1, 2024 | kellogg.northwestern.eduKRegenerx Biopharmaceuticals Inc RGRXDNovember 5, 2023 | morningstar.comMRegenerx Biopharm In (RGRXD)October 30, 2023 | investing.comLIB Therapeutics and Hasten Biopharmaceutical Company Announce $325 Million Strategic Collaboration to Develop and Commercialize Lerodalcibep in Greater ChinaSeptember 21, 2023 | businesswire.comJeannette company becomes leader in recycling biopharmaceutical wasteSeptember 18, 2023 | triblive.comTRGRX RegeneRx Biopharmaceuticals, Inc.August 26, 2023 | seekingalpha.comRegeneRx Effects Reverse Stock Split and Terminates SEC Reporting ObligationsAugust 15, 2023 | finance.yahoo.comRegeneRx Receives Stockholder Approval for Reverse Stock SplitAugust 8, 2023 | finance.yahoo.comRegeneRx To Extend Consent Solicitation VoteAugust 1, 2023 | finance.yahoo.comBristol-Myers to Split Off Mead JohnsonJuly 6, 2023 | thestreet.comPlasmaTech Biopharmaceuticals (PTBI) Stock Rises on 'Buy' Rating Coverage InitiationMay 19, 2023 | thestreet.comFirst Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259April 13, 2023 | finance.yahoo.comBiopharmaceutical (Biopharma) Aseptic Filling Machine Market Drivers, Risks, Potential Outcomes, and Major Segments for 2030April 7, 2023 | marketwatch.comBiopharmaceutical Third Party Logistics (3PL) Market | 2023-2029April 7, 2023 | marketwatch.comCURIA, CORNING BOOST BIOPHARMACEUTICAL CONTINUOUS-FLOW DEVELOPMENT, MANUFACTURINGApril 4, 2023 | bernama.comB2023 Biopharmaceutical Culture Media Market Top Countries Survey Predicts STRONG GROWTH bY 2029March 1, 2023 | marketwatch.comBiopharmaceutical Market 2023 ACCURATE PREDICTIONS with Fastest-Growing Segment till 2028February 25, 2023 | marketwatch.comBiopharmaceutical Market 2023: Market Specific Analysis and Perception Study for Players till 2027February 24, 2023 | marketwatch.comBiopharmaceutical Fermentation Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)February 12, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEVOK, AKRX, BLCM, JAGX, and RGRX Company DescriptionsAkorn NASDAQ:AKRXAkorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.Bellicum Pharmaceuticals NASDAQ:BLCMBellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.Evoke Pharma NASDAQ:EVOK$5.08 -0.01 (-0.20%) Closing price 04:00 PM EasternExtended Trading$5.10 +0.01 (+0.30%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Jaguar Animal Health NASDAQ:JAGX$1.91 +0.05 (+2.69%) Closing price 04:00 PM EasternExtended Trading$1.90 0.00 (-0.26%) As of 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.RegeneRx Biopharmaceuticals OTCMKTS:RGRX$0.16 +0.16 (+80,400.00%) As of 09/16/2025 10:07 AM EasternRegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Bloom Energy Booms on AI Power Demand and Analyst Upgrades Can Apple’s iPhone 17 and AI Push Its Stock to New Highs? New Catalysts Build Positive Pressure on Intel Stock Oracle to Hit $1 Trillion Valuation in 2025: Here’s Why General Mills Is a Generational Opportunity for Income Investors Nike’s Red-Hot Analyst Buzz: Is a Comeback Brewing? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
